GlassScriptPhysician profile
Thomas Sin Young Chung
NPI 1114378171
$4,799.57
in general payments reported to CMS, 2019-2025
28 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $643 · 2022: $1,183 · 2023: $2,028 · 2024: $629 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,908 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,907.81 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $883.21 | 2021-2025 | |
| Amgen INC. | $602.49 | 2021-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $472.99 | 2022-2024 | Verquvo |
| Scpharmaceuticals INC. | $371.34 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $332.01 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $260.39 | 2021-2023 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $248.42 | 2021-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $229.61 | 2022-2024 | Farxiga, Atacand, Wainua |
| Lexicon Pharmaceuticals, INC. | $196.82 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $173.37 | 2022-2025 | |
| Pfizer INC. | $160.58 | 2021-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $126.96 | 2022-2023 | Arcalyst |
| Medtronic, INC. | $124.45 | 2021-2025 | Symplicity G3, Onyx Frontier, Reveal Linq |
| Esperion Therapeutics, INC. | $94.98 | 2021-2023 | Nexletol |
| Cvrx, INC. | $79.63 | 2022-2024 | Barostim Neo System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $74.46 | 2021-2024 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $64.03 | 2023-2024 | Xarelto |
| Abbott Laboratories | $56.53 | 2021-2022 | |
| Philips North America LLC | $45.80 | 2022-2024 | (5091) Amb Mon & Diag Und |
| Astellas Pharma US INC | $33.56 | 2024 | |
| Sanofi-Aventis U.S. LLC | $32.44 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $28.03 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $25.10 | 2024 | Amvuttra |
| Boston Scientific Corporation | $17.88 | 2021 | |
| Atricure, INC. | $17.82 | 2025 | Atriclip Laa Exclusion System |
| Bard Peripheral Vascular, INC. | $16.99 | 2024 | Denali Vena Cava Filter |
| Baxter Healthcare | $16.43 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Irhythm Technologies, INC. | $13.25 | 2024 | Zio Xt Patch, Zio Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.